The gene expression signature associated with TP53 mutation/deletion in chronic lymphocytic leukaemia is dominated by the under-expression of TP53 and other genes on chromosome 17p

British Journal of Haematology

Volumn 160, Issue 1, 2013, Pages 53-62

  Lin, Ke ^a,b   Lane, Brian ^a   Carter, Anthony ^b   Johnson, Gillian G ^a,b   Onwuazor, Obiageli ^a   Oates, Melanie ^a   Zenz, Thorsten ^c,d   Stilgenbauer, Stephan ^d   Atherton, Mark ^e   Douglas, Angela ^e   Ebrahimi, Bahram ^a   Sherrington, Paul D ^a,b   Pettitt, Andrew R ^a,b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^d UNIVERSITY OF ULM   (Germany)

^e LIVERPOOL WOMEN S HOSPITAL   (United Kingdom)

Author keywords

Chronic lymphocytic leukaemia; Gene expression profile; Microarray; TP53 deletion; TP53 mutation

Indexed keywords

GENOMIC DNA; PROTEIN P53;

ARTICLE; CHROMOSOME 17P; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DNA SEQUENCE; GENE CONTROL; GENE DELETION; GENE EXPRESSION PROFILING; GENE FREQUENCY; GENE FUNCTION; GENETIC ASSOCIATION; MICROARRAY ANALYSIS; MOLECULAR PATHOLOGY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE; UNINDEXED SEQUENCE; WILD TYPE;

CHROMOSOMES, HUMAN, PAIR 17; GENE DELETION; GENES, P53; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MICROARRAY ANALYSIS; TRANSCRIPTOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84870787033     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12092     Document Type: Article

References (54)

1. Andersen, C.L., Jensen, J.L. & Orntoft, T.F. (2004) Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Research, 64, 5245-5250.
2. Benjamini, Y. & Hochberg, Y. (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society: Series B, 57, 289-300.
3. Blandino, G., Levine, A.J. & Oren, M. (1999) Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene, 18, 477-485.
4. Brosh, R. & Rotter, V. (2009) When mutants gain new powers: news from the mutant p53 field. Nature Reviews Cancer, 9, 701-713.
5. Bykov, V.J., Lambert, J.M., Hainaut, P. & Wiman, K.G. (2009) Mutant p53 rescue and modulation of p53 redox state. Cell Cycle, 8, 2509-2517.
6. Carter, A., Lin, K., Sherrington, P.D. & Pettitt, A.R. (2004) Detection of p53 dysfunction by flow cytometry in chronic lymphocytic leukaemia. British Journal of Haematology, 127, 425-428.
7. Carter, A., Lin, K., Sherrington, P.D., Atherton, M., Pearson, K., Douglas, A., Burford, A., Brito-Babapulle, V., Matutes, E., Catovsky, D. & Pettitt, A.R. (2006) Imperfect correlation between p53 dysfunction and deletion of TP53 and ATM in chronic lymphocytic leukaemia. Leukemia, 20, 737-740.
8. Chang, J.W., Chen, Y.C., Chen, C.Y., Chen, J.T., Chen, S.K. & Wang, Y.C. (2000) Correlation of genetic instability with mismatch repair protein expression and p53 mutations in non-small cell lung cancer. Clinical Cancer Research, 6, 1639-1646.
9. Chène, P., Ory, K., Rüedi, D., Soussi, T. & Hegi, M.E. (1999) Functional analyses of a unique p53 germline mutant (Y236D) associated with a familial brain tumor syndrome. International Journal of Cancer, 82, 17-22.
10. Cheok, C.F., Verma, C.S., Baselga, J. & Lane, D.P. (2010) Translating p53 into the clinic. Nature Reviews Clinical Oncology, 8, 25-37.
11. Chiorazzi, N., Rai, K. & Ferrarini, M. (2005) Chronic lymphocytic leukemia. New England Journal of Medicine, 352, 804-815.
12. Dicker, F., Schnittger, S., Haferlach, T., Kern, W. & Schoch, C. (2006) Immunostimulatory oligonucleotide-induced metaphase cytogenetics detect chromosomal aberrations in 80% of CLL patients: a study of 132 CLL cases with correlation to FISH, IgVH status, and CD38 expression. Blood, 108, 3152-3160.
13. Dicker, F., Herholz, H., Schnittger, S., Nakao, A., Patten, N., Wu, L., Kern, W., Haferlach, T. & Haferlach, C. (2009) The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype. Leukemia, 23, 117-124.
14. Döhner, H., Stilgenbauer, S., Benner, A., Leupolt, E., Kröber, A., Bullinger, L., Döhner, K., Bentz, M. & Lichter, P. (2000) Genomic aberrations and survival in chronic lymphocytic leukemia. New England Journal of Medicine, 343, 1910-1916.
15. El-Deiry, W.S., Kern, S.E., Pietenpol, J.A., Kinzler, K.W. & Vogelstein, B. (1992) Definition of a consensus binding site for p53. Nature Genetics, 1, 45-49.
16. Fabris, S., Mosca, L., Todoerti, K., Cutrona, G., Lionetti, M., Intini, D., Matis, S., Colombo, M., Agnelli, L., Gentile, M., Spriano, M., Callea, V., Festini, G., Molica, S., Deliliers, G.L., Morabito, F., Ferrarini, M. & Neri, A. (2008) Molecular and transcriptional characterization of 17p loss in B-cell chronic lymphocytic leukemia. Genes Chromosomes Cancer, 47, 781-793.
17. Gandini, D., Aguiari, G.L., Cuneo, A., Piva, R., Castoldi, G.L. & del Senno, L. (1994) Novel small deletions of the p53 gene in late-stage B-cell chronic lymphocytic leukaemia. British Journal of Haematology, 88, 881-885.
18. Gentleman, R.C., Carey, V.J., Bates, D.M., Bolstad, B., Dettling, M., Dudoit, S., Ellis, B., Gautier, L., Ge, Y., Gentry, J., Hornik, K., Hothorn, T., Huber, W., Iacus, S., Irizarry, R., Leisch, F., Li, C., Maechler, M., Rossini, A.J., Sawitzki, G., Smith, C., Smyth, G., Tierney, L., Yang, J.Y. & Zhang, J. (2004) Bioconductor: open software development for computational biology and bioinformatics. Genome Biology, 5, R80.
19. Grever, M.R., Lucas, D.M., Dewald, G.W., Neuberg, D.S., Reed, J.C., Kitada, S., Flinn, I.W., Tallman, M.S., Appelbaum, F.R., Larson, R.A., Paietta, E., Jelinek, D.F., Gribben, J.G. & Byrd, J.C. (2007) Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US intergroup phase III trial E2997. Journal of Clinical Oncology, 25, 799-804.
20. Gyorffy, B., Molnar, B., Lage, H., Szallasi, Z. & Eklund, A.C. (2009) Evaluation of microarray preprocessing algorithms based on concordance with RT-PCR in clinical samples. PLoS ONE, 4, e5645.
21. Harvey, M., Vogel, H., Morris, D., Bradley, A., Bernstein, A. & Donehower, L.A. (1995) A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53-deficient mice. Nature Genetics, 9, 305-311.
22. Haslinger, C., Schweifer, N., Stilgenbauer, S., Döhner, H., Lichter, P., Kraut, N., Stratowa, C. & Abseher, R. (2004) Microarray gene expression profiling of B-cell chronic lymphocytic leukemia subgroups defined by genomic aberrations and VH mutation status. Journal of Clinical Oncology, 22, 3937-3949.
23. Irizarry, R.A., Hobbs, B., Collin, F., Beazer-Barclay, Y.D., Antonellis, K.J., Scherf, U. & Speed, T.P. (2003) Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Research, 31, e15.
24. Jego, N., Thomas, G. & Hamelin, R. (1993) Short direct repeats flanking deletions, and duplicating insertions in p53 gene in human cancers. Oncogene, 8, 209-213.
25. Kienle, D.L., Korz, C., Hosch, B., Benner, A., Mertens, D., Habermann, A., Kröber, A., Jäger, U., Lichter, P., Döhner, H. & Stilgenbauer, S. (2005) Evidence for distinct pathomechanisms in genetic subgroups of chronic lymphocytic leukemia revealed by quantitative expression analysis of cell cycle, activation, and apoptosis-associated genes. Journal of Clinical Oncology, 23, 3780-3792.
26. Kim, E. & Deppert, W. (2004) Transcriptional activities of mutant p53: when mutations are more than a loss. Journal of Cellular Biochemistry, 93, 878-886.
27. Li, R., Sutphin, P.D., Schwartz, D., Matas, D., Almog, N., Wolkowicz, R., Goldfinger, N., Pei, H., Prokocimer, M. & Rotter, V. (1998) Mutant p53 protein expression interferes with p53-independent apoptotic pathways. Oncogene, 16, 3269-3277.
28. Lin, K., Rockliffe, N., Johnson, G.G., Sherrington, P.D. & Pettitt, A.R. (2008) Hsp90 inhibition has opposing effects on wild-type and mutant p53 and induces p21 expression and cytotoxicity irrespective of p53/ATM status in chronic lymphocytic leukaemia cells. Oncogene, 27, 2445-2455.
29. Liu, G., McDonnell, T.J., Montes de Oca Luna, R., Kapoor, M., Mims, B., El-Naggar, A.K. & Lozano, G. (2000) High metastatic potential in mice inheriting a targeted p53 missense mutation. Proceedings of the National Academy of Sciences of the United States of America, 97, 4174-4179.
30. Lu, C. & El-Deiry, W.S. (2009) Targeting p53 for enhanced radio- and chemo-sensitivity. Apoptosis, 14, 597-606.
31. Malcikova, J., Smardova, J., Rocnova, L., Tichy, B., Kuglik, P., Vranova, V., Cejkova, S., Svitakova, M., Skuhrova Francova, H., Brychtova, Y., Doubek, M., Brejcha, M., Klabusay, M., Mayer, J., Pospisilova, S. & Trbusek, M. (2009) Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage. Blood, 114, 5307-5314.
32. Matas, D., Sigal, A., Stambolsky, P., Milyavsky, M., Weisz, L., Schwartz, D., Goldfinger, N. & Rotter, V. (2001) Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis. The EMBO Journal, 20, 4163-4172.
33. Meek, D.W. (2009) Tumour suppression by p53: a role for the DNA damage response? Nature Reviews Cancer, 9, 714-723.
34. Petitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S.V., Hainaut, P. & Olivier, M. (2007a) Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Human Mutation, 28, 622-629.
35. Petitjean, A., Achatz, M.I., Borresen-Dale, A.L., Hainaut, P. & Olivier, M. (2007b) TP53 mutations in Human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene, 26, 2157-2165.
36. Riley, T., Sontag, E., Chen, P. & Levine, A. (2008) Transcriptional control of human p53-regulated genes. Nature Reviews Molecular Cell Biology, 9, 402-412.
37. Rossi, D., Cerri, M., Deambrogi, C., Sozzi, E., Cresta, S., Rasi, S., De Paoli, L., Spina, V., Gattei, V., Capello, D., Forconi, F., Lauria, F. & Gaidano, G. (2009) The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness. Clinical Cancer Research, 15, 995-1004.
38. Scian, M.J., Stagliano, K.E., Ellis, M.A., Hassan, S., Bowman, M., Miles, M.F., Deb, S.P. & Deb, S. (2004) Modulation of gene expression by tumor-derived p53 mutants. Cancer Research, 64, 7447-7454.
39. Scian, M.J., Stagliano, K.E., Anderson, M.A., Hassan, S., Bowman, M., Miles, M.F., Deb, S.P. & Deb, S. (2005) Tumor-derived p53 mutants induce NF-kappaB2 gene expression. Molecular and Cellular Biology, 25, 10097-10110.
40. Smyth, G.K. (2004) Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Statistical Applications in Genetics and Molecular Biology, 3, Article3.
41. Stankovic, T., Hubank, M., Cronin, D., Stewart, G.S., Fletcher, D., Bignell, C.R., Alvi, A.J., Austen, B., Weston, V.J., Fegan, C., Byrd, P.J., Moss, P.A. & Taylor, A.M. (2004) Microarray analysis reveals that TP53- and ATM-mutant B-CLLs share a defect in activating proapoptotic responses after DNA damage but are distinguished by major differences in activating prosurvival responses. Blood, 103, 291-300.
42. Steele, A.J., Prentice, A.G., Hoffbrand, A.V., Yogashangary, B.C., Hart, S.M., Nacheva, E.P., Howard-Reeves, J.D., Duke, V.M., Kottaridis, P.D., Cwynarski, K., Vassilev, L.T. & Wickremasinghe, R.G. (2008) p53-mediated apoptosis of CLL cells: evidence for a transcription-independent mechanism. Blood, 112, 3827-3834.
43. Stilgenbauer, S., Zenz, T., Winkler, D., Bühler, A., Busch, R., Fingerle-Rowson, G., Fischer, K., Fink, A.M., Jäger, U., Böttcher, S., Kneba, M., Wenger, M., Mendila, M., Hallek, M. & Döhner, H. (2008) Genomic aberrations, VH mutation status and outcome after fludarabine and cyclophosphamide (FC) or FC plus Rituximab (FCR) in the CLL8 trial [ASH Annual Meeting Abstract]. Blood, 112, 781a.
44. Strano, S., Dell'Orso, S., Di Agostino, S., Fontemaggi, G., Sacchi, A. & Blandino, G. (2007) Mutant p53:an oncogenic transcription factor. Oncogene, 26, 2212-2219.
45. Tepper, C.G., Gregg, J.P., Shi, X.B., Vinall, R.L., Baron, C.A., Ryan, P.E., Desprez, P.Y., Kung, H.J. & deVere White, R.W. (2005) Profiling of gene expression changes caused by p53 gain-of-function mutant alleles in prostate cancer cells. Prostate, 65, 375-389.
46. Toledo, F. & Wahl, G.M. (2006) Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nature Reviews Cancer, 6, 909-923.
47. Vogelstein, B., Lane, D. & Levine, A.J. (2000) Surfing the p53 network. Nature, 408, 307-310.
48. Wilson, C.L. & Miller, C. (2005) Simpleaffy: a BioConductor package for Affymetrix Quality Control and data analysis. Bioinformatics, 21, 3683-3685.
49. Yamanoshita, O., Kubota, T., Hou, J., Ping, Y.M., Zhang, X.L., Li, X.P., Li, S.S., Li, X.X., Zhu, D.C., Fukushima, Y. & Nakajima, T. (2005) DHPLC is superior to SSCP in screening p53 mutations in esophageal cancer tissues. International Journal of Cancer, 114, 74-79.
50. Zache, N., Lambert, J.M., Rökaeus, N., Shen, J., Hainaut, P., Bergman, J., Wiman, K.G. & Bykov, V.J. (2008) Mutant p53 targeting by the low molecular weight compound STIMA-1. Molecular Oncology, 2, 70-80.
51. Zenz, T., Krober, A., Scherer, K., Häbe, S., Bühler, A., Benner, A., Denzel, T., Winkler, D., Edelmann, J., Schwänen, C., Döhner, H. & Stilgenbauer, S. (2008) Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood, 112, 3322-3329.
52. Zenz, T., Hoth, P., Busch, R., Helfrich, H., Winkler, D., Bühler, A., Patten, N., Truong, S., Wu, L., Fingerle-Rowson, G., Fischer, K., Fink, A.M., Jäger, U., Böttcher, S., Kneba, M., Wenger, M.K., Mendila, M., Hallek, M., Döhner, H. & Stilgenbauer, S. (2009a) TP53 mutations and outcome after fludarabine and cyclophosphamide (FC) or FC plus rituximab (FCR) in the CLL8 Trial of the GCLLSG [ASH Annual Meeting Abstract]. Blood, 114, 1267a.
53. Zenz, T., Häbe, S., Denzel, T., Mohr, J., Winkler, D., Bühler, A., Sarno, A., Groner, S., Mertens, D., Busch, R., Hallek, M., Döhner, H. & Stilgenbauer, S. (2009b) Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood, 114, 2589-2597.
54. Zenz, T., Vollmer, D., Trbusek, M., Smardova, J., Benner, A., Soussi, T., Helfrich, H., Heuberger, M., Hoth, P., Fuge, M., Denzel, T., Häbe, S., Malcikova, J., Kuglik, P., Truong, S., Patten, N., Wu, L., Oscier, D., Ibbotson, R., Gardiner, A., Tracy, I., Lin, K., Pettitt, A., Pospisilova, S., Mayer, J., Hallek, M., Döhner, H. & Stilgenbauer, S. European Research Initiative on CLL (ERIC). (2010) TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations. Leukemia, 24, 2072-2079.